Amgen's most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $202.50 short call and a strike $207.50 long call offers a potential 69.49% return on risk over the next 24 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $202.50 by expiration. The full premium credit of $2.05 would be kept by the premium seller. The risk of $2.95 would be incurred if the stock rose above the $207.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is at 67.83 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Should Amgen Finally Buy Alexion Pharmaceuticals?
Sun, 25 Aug 2019 15:31:00 +0000
One of biotech's longest-running buyout rumors is picking up steam again.
3 Reasons Why Amgen Could Actually Acquire Alexion
Sat, 24 Aug 2019 11:29:00 +0000
Rumors that Amgen plans to buy Alexion might not become reality. But a deal would make a lot of sense.
Why Alexion Makes Sense As A Target, But Amgen Doesn't As A Buyer
Fri, 23 Aug 2019 20:10:39 +0000
Alexion Pharmaceuticals is likely "on the radar" as a takeover candidate, but biotech company Amgen doesn't fit logically as an acquirer, an analyst said. Alexion stock toppled Friday.
Amgen’s Alexion Acquisition: Does It Make Sense?
Fri, 23 Aug 2019 19:26:18 +0000
On August 21, Spanish website Intereconomia reported that Amgen would be announcing its acquisition of Alexion Pharmaceuticals in the next few days.
Amgen Presents Positive Data From Rituxan Biosimilar Study
Fri, 23 Aug 2019 14:36:02 +0000
Amgen (AMGN) markets Mvasi and Kanjinti, biosimilar versions of Avastin and Herceptin, respectively in the United States, and Kanjinti and Amgevita, biosimilar of Humira, in the EU.
Also on Market Tamer…
Follow Us on Facebook